Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $34.82 and last traded at $34.97, with a volume of 72,896 shares. The stock had previously closed at $33.52.

A number of analysts have recently issued reports on ASMB shares. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, August 18th. Finally, Zacks Investment Research downgraded shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 14th.

The stock has a 50 day moving average price of $26.13 and a 200 day moving average price of $24.08. The stock’s market capitalization is $606.35 million.

Several institutional investors and hedge funds have recently made changes to their positions in ASMB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Assembly Biosciences during the first quarter worth approximately $122,000. FNY Partners Fund LP acquired a new position in Assembly Biosciences during the first quarter worth approximately $140,000. Nationwide Fund Advisors acquired a new position in Assembly Biosciences during the second quarter worth approximately $161,000. Parametric Portfolio Associates LLC increased its position in Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Assembly Biosciences during the second quarter worth approximately $212,000. 72.27% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Assembly Biosciences, Inc. (ASMB) Reaches New 1-Year High at $34.82” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/01/assembly-biosciences-inc-asmb-reaches-new-1-year-high-at-34-82.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Stock Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related stocks with our FREE daily email newsletter.